Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]

This article refers to:

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies

Ferrufino CP, Munakata J, Wei W, et al. Clinicoecon Outcomes Res. 2018;10: 805—819.

On page 810, Table 4, Drug costs column, Methotrexate, the Unit WAC was listed as $1 however it should have been $2.36. The updated table is as follows:

Table 4 Drug cost summary

Drug costs	Dose	Package size	WAC	Unit WAC	Annual costa	Annual price increaseb	Net WAC with ICER specified discountsc
Non-TNFi biologics
Abatacept (SC)	125.0 mg	4 syringes	$4,131	$1,033	$57,359	13.5%	$2892
Abatacept (IV)	250.0 mg	1 vial	$1,046	$1,046	$49,906	13.5%	$732
Rituximab (IV)	100.0 mg	1 vial	$835	$835	$50,863	5.0%	$710
Sarilumab (SC)	150.0 mg	2 syringes	$3,159	$1,580	$43,317	5.3%	$2,527
Sarilumab (SC)	200.0 mg	2 syringes	$3,159	$1,580	$41,208	5.3%	$2,527
Tocilizumab (SC)	162.0 mg	1 syringe	$985	$985	$40,117	8.4%	$788
Tocilizumab (IV)	80.0 mg	1 vial	$417	$417	$39,038	6.3%	$333
TNFi biologics
Adalimumab (SC)	40.0 mg	6 pens	$14,616	$2,436	$73,542	14.9%	$10,231
Certolizumab pegol (SC)	200.0 mg	3 syringe kits	$12,132	$4,044	$68,232	9.9%	$8,493
Etanercept (SC)	50.0 mg	4 syringes	$4,872	$1,218	$59,953	16.4%	$3,410
Golimumab (SC)	50.0 mg	1 syringe	$4,520	$4,520	$68,955	14.5%	$3,164
Golimumab (IV)	50.0 mg	1 vial	$1,734	$1,734	$59,952	14.5%	$1,213
Infliximab (IV)	100.0 mg	1 vial	$1,168	$1,168	$37,228	8.3%	$817
Infliximab (IV) biosimilar	100.0 mg	1 vial	$889	$889	$28,332	8.3%	$622
JAK inhibitors
Tofacitinib (Oral)	5.0 mg	60 tablets	$4,099	$63	$46,213	15.5%	$3,891
csDMARDs
Methotrexate	2.5 mg	100 tablets	$236	$2.36	$1,139	0.0%	Not applicable
Concomitant medication:
Prednisone	10.0 mg	1 tablet	$0.19	$0.19	$69	0.0%	Not applicable

a Notes: Assuming full compliance, no fees, discounts or any patient out of pocket contributions.

b Based on the compound annual growth rate for drug prices between January 2013 to January 2016.³⁷

c Discounts: TNFi: 30%, CD-20 directed cytolytic antibody: 15%, T-cell inhibitors: 30%, IL-6 inhibitors: 20%, JAK inhibitors: 5%.

Abbreviations: csDMARD, conventional synthetic disease-modifying antirheumatic drug; IV, intravenous; JAK, janus kinase; SC, subcutaneous; TNFi, tumor necrosis factor inhibitor; WAC, wholesale acquisition cost.

On page 817, Table S2, the monitoring costs for (A) csD-MARD-IR and (B) TNF-IR were changed. The updated table is as follows:

Supplementary material

Table S2 Budget impact by cost metric in years 1–5, in (A) csDMARD-IR, (B) TNF-IR populations, (C) combination (pooled csDMARD-IR and TNF-IR), and (D) monotherapy (csDMARD-IR or TNF-IR)

Cost by metric	Year 1	Year 2	Year 3	Year 4	Year 5	Years 1–5
(A) csDMARD-IR
DMARDs
Base-case	$20,254,095	$20,824,169	$21,474,496	$22,205,356	$23,026,048	$107,784,164
Projected	$20,226,459	$20,764,870	$21,378,464	$22,066,321	$22,836,306	$107,272,419
Net	−$27,636	−$59,299	−$96,033	−$139,035	−$189,742	−$511,744
Administration
Base-case	$223,299	$223,756	$224,254	$224,677	$224,996	$1,120,982
Projected	$222,182	$221,518	$220,890	$220,184	$219,371	$1,104,146
Net	−$1,116	−$2,238	−$3,364	−$4,494	−$5,625	−$16,836
Concomitant medications
Base-case	$8,699	$8,717	$8,736	$8,752	$8,765	$43,668
Projected	$8,696	$8,712	$8,729	$8,743	$8,753	$43,634
Net	−$3	−$5	−$7	−$9	−$12	−$35
Monitoring
Base-case	$61,176	$61,301	$61,438	$61,554	$61,641	$307,110
Projected	$61,321	$61,593	$61,876	$62,139	$62,373	$309,302
Net	$145	$291	$438	$585	$732	$2,192
Total costs
Base-case	$20,547,268	$21,117,943	$21,768,924	$22,500,339	$23,321,449	$109,255,924
Projected	$20,518,659	$21,056,693	$21,669,959	$22,357,386	$23,126,803	$108,729,500
Net	−$28,610	−$61,249	−$98,965	−$142,953	−$194,646	−$526,424
(B) TNF-IR
DMARDs
Base-case	$15,608,855	$16,031,438	$16,510,886	$17,046,450	$17,644,182	$82,841,812
Projected	$15,592,910	$15,996,734	$16,453,889	$16,962,801	$17,528,531	$82,534,865
Net	−$15,945	−$34,705	−$56,997	−$83,649	−$115,651	−$306,948
Administration
Base-case	$228,199	$228,667	$229,176	$229,608	$229,934	$1,145,585
Projected	$227,058	$226,380	$225,738	$225,016	$224,186	$1,128,379
Net	−$1,141	−$2,287	−$3,438	−$4,592	−$5,748	−$17,206
Concomitant medications
Base-case	$7,206	$7,220	$7,236	$7,250	$7,260	$36,173
Projected	$7,204	$7,218	$7,233	$7,245	$7,254	$35,154
Net	−$2	−$2	−$3	−$5	−$6	−$9
Monitoring
Base-case	$55,731	$55,846	$55,970	$56,075	$56,155	$279,777
Projected	$55,833	$56,050	$56,277	$56,485	$56,668	$281,313
Net	$102	$204	$307	$410	$513	$1,536
Total costs
Base-case	$15,899,992	$16,323,171	$16,803,268	$17,339,384	$17,937,532	$84,303,347
Projected	$15,883,006	$16,286,381	$16,743,137	$17,251,548	$17,816,639	$83,980,711
Net	−$16,986	−$36,790	−$60,131	−$87,837	−$120,893	−$322,637
(C) Combination therapy (pooled csDMARD-IR and TNF-IR)
DMARDs
Base-case	$36,177,639	$37,182,732	$38,327,255	$39,610,950	$41,049,549	$192,348,125
Projected	$36,132,484	$37,085,458	$38,169,098	$39,381,082	$40,734,673	$191,502,794
Net	−$45,155	−$97,274	−$158,157	−$229,868	−$314,876	−$845,331
Administration
Base-case	$442,973	$443,881	$444,869	$445,708	$446,340	$2,223,771
Projected	$440,758	$439,442	$438,196	$436,794	$435,182	$2,190,372
Net	−$2,215	−$4,439	−$6,673	−$8,914	−$11,159	−$33,399
Concomitant medications
Base-case	$15,932	$15,965	$16,000	$16,031	$16,053	$79,981
Projected	$15,929	$15,957	$15,989	$16,016	$16,035	$79,925
Net	−$3	−$8	−$11	−$15	−$19	−$56
Monitoring
Base-case	$116,023	$116,260	$116,519	$116,739	$116,905	$582,446
Projected	$116,274	$116,765	$117,277	$117,752	$118,172	$586,240
Net	$252	$504	$758	$1,013	$1,262	$3,794
Total costs
Base-case	$36,752,567	$37,758,838	$38,904,643	$40,189,428	$41,628,848	$195,234,324
Projected	$36,705,445	$37,657,622	$38,740,560	$39,951,644	$41,304,062	$194,359,332
Net	−$47,122	−$101,216	−$164,083	−$237,784	−$324,786	−$874,992
Cost by metric	Year 1	Year 2	Year 3	Year 4	Year 5	Years 1–5
(D) Monotherapy (csDMARD-IR or TNF-IR)
DMARDs
Base-case	$10,746,634	$11,047,944	$11,391,063	$11,775,969	$12,207,397	$57,169,007
Projected	$10,732,920	$11,018,425	$11,343,110	$11,706,334	$12,112,089	$56,912,879
Net	−$13,714	−$29,518	−$47,952	−$69,635	−$95,308	−$256,127
Administration
Base-case	$132,892	$133,164	$133,461	$133,712	$133,902	$667,131
Projected	$132,228	$131,833	$131,459	$131,038	$130,555	$657,112
Net	−$664	−$1,332	−$2,002	−$2,674	−$3,348	−$10,020
Concomitant medications
Base-case	$4,780	$4,789	$4,800	$4,809	$4,816	$23,994
Projected	$4,779	$4,787	$4,797	$4,805	$4,810	$23,978
Net	−$1	−$2	−$3	−$4	−$6	−$17
Monitoring
Base-case	$5,902	$5,914	$5,927	$5,938	$5,947	$29,628
Projected	$6,025	$6,161	$6,298	$6,434	$6,567	$31,486
Net	$123	$247	$371	$496	$621	$1,858
Total costs
Base-case	$10,890,208	$11,191,811	$11,535,251	$11,920,429	$12,352,061	$57,889,760
Projected	$10,875,951	$11,161,206	$11,485,664	$11,848,611	$12,254,022	$57,625,454
Net	−$14,256	−$30,605	−$49,586	−$71,818	−$98,040	−$264,306

Abbreviations: csDMARD, conventional synthetic disease-modifying antirheumatic drug; DMARD, disease-modifying antirheumatic drug; IR, inadequate response; TNF, tumor necrosis factor inhibitor.